IMPACT BIOMEDICAL INC.

IBO · NYSE · SIC 2834: Pharmaceutical Preparations
50
SEC Filings

Business Summary

PART I ITEM 1 - BUSINESS Overview Impact Biomedical Inc. (IBO. Impact, Impact BioMedical, we, us, our or the Company) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships, and currently trades on the NYSE American under ticker symbol IBO. By leveraging technology and new science with strategic par...

Next Earnings

Q2 FY2026 — expected 2026-07-22

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionIBOdiscussed_in_filing Trusted Computing
topic_mentionIBOdiscussed_in_filing Blockchain & Crypto
topic_mentionIBOdiscussed_in_filing Regulation
topic_mentionIBOdiscussed_in_filing Healthcare & Bio
topic_mentionIBOdiscussed_in_filing Platform & Ecosystem
topic_mentionIBOdiscussed_in_filing Networking
topic_mentionIBOdiscussed_in_filing Sovereign & Government
topic_mentionIBOdiscussed_in_filing Trusted Computing
topic_mentionIBOdiscussed_in_filing Blockchain & Crypto
topic_mentionIBOdiscussed_in_filing Regulation
topic_mentionIBOdiscussed_in_filing Healthcare & Bio
topic_mentionIBOdiscussed_in_filing Platform & Ecosystem
topic_mentionIBOdiscussed_in_filing Networking
topic_mentionIBOdiscussed_in_filing Sovereign & Government
topic_mentionIBOdiscussed_in_filing Trusted Computing
topic_mentionIBOdiscussed_in_filing Blockchain & Crypto
topic_mentionIBOdiscussed_in_filing Regulation
topic_mentionIBOdiscussed_in_filing Healthcare & Bio
topic_mentionIBOdiscussed_in_filing Platform & Ecosystem
topic_mentionIBOdiscussed_in_filing Networking

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-112025-12-310001493152-26-009711EDGAR42K words
2025-03-282024-12-310001641172-25-001199EDGAR—
2024-02-202023-12-310001493152-24-007229EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001493152-25-021286EDGAR19K words
2025-08-142025-06-300001641172-25-023809EDGAR—
2025-05-142025-03-310001641172-25-010276EDGAR—
2024-11-122024-09-300001493152-24-044792EDGAR—
2024-08-132024-06-300001493152-24-031635EDGAR—
2024-05-102024-03-310001493152-24-018663EDGAR—
2023-11-132023-09-300001493152-23-040547EDGAR—
2023-10-052023-06-300001493152-23-036365EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-040001493152-26-008879EDGAR1K words
2025-11-060001493152-25-021066EDGAR—
2025-10-270001493152-25-019734EDGAR—
2025-07-280001641172-25-021085EDGAR—
2025-06-230001641172-25-016002EDGAR—
2025-04-030001641172-25-002577EDGAR—
2025-03-280001641172-25-001060EDGAR—
2025-03-130001493152-25-010190EDGAR—
2025-01-290001493152-25-004161EDGAR—
2024-11-040001493152-24-043558EDGAR—

50 total filings indexed. 29 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001834105
TickerIBO
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedNV

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 6e4ec0c02e4ac3df3dfef015da69788516a1f8c4688304ed30e6c0b41f5c420c
parent: 0ab10af6f91ed356593a8c451c3028e6db7ac4bc931cda096cf6e1188e57e23d
content hash: b32e0fab4fa53d03da54d65537c0027b6b466785361e925a25ac56a8304724fb
signed: 2026-04-13T04:45:36.956Z
sources: 11 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf